Companies › Eluciderm
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ELU42 Tankyrase inhibitor combined with derivatized hyaluronic acid (DHA77) excipient for topica | TNKS | Phase 1 | Diabetic Foot Ulcer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07396376 | ELU42 | Phase 1 | Diabetic Foot Ulcer | Metabolic and endocrine | Jun 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.